Annovis Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Annovis Bio sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Annovis Bio: 7 sponsored US clinical trials, 2 recruiting.
Annovis Bio sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Deep Brain Stimulation, with 1 trials.
Upper-quartile sponsor footprint
Annovis Bio sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Study of Buntanetap in Participants With PD
NCT07284784
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
NCT05686044
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
NCT05357989
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
NCT04524351
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
NCT02925650
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
NCT01072812
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Annovis Bio pipeline
2 recruiting of 7 indexed (29% open); 4 completed (57%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Deep Brain Stimulation (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Annovis Bio: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Annovis Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Ascendis Pharma Endocrinology Division A/S · 29% recruiting · 7 trials
Related
What to do with this Annovis Bio page
7 registered trials is a research-attention snapshot, not an endorsement of Annovis Bio or any single study.
- 2 of Annovis Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Deep Brain Stimulation is the condition Annovis Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Deep Brain Stimulation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Annovis Bio pipeline card: 7 registered trials from official public datasets.Report a data error.